Crossmark

New drugs for Alzheimer’s disease: Aducanumab or Donanemab?

Crossref DOI link: https://doi.org/10.61186/phypha.28.3.219

Published Online: 2024-09-01

Update policy: https://doi.org/10.61186/crossmark-policy

Authors

Joodaki, Mehran http://orcid.org/0000-0001-9062-2716
Merati Shirazi, Mona

Hosseini, Nasrin
License Information

Version of Record valid from 2000-08-13
More Information

Journal Owner: Society of Physiology and Pharmacology

Journal Publisher: Apex Publishing